250 related articles for article (PubMed ID: 37114050)
1. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
[TBL] [Abstract][Full Text] [Related]
2. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
Front Immunol; 2024; 15():1365027. PubMed ID: 38292867
[TBL] [Abstract][Full Text] [Related]
4. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.
Fei K; Ni H; Zhu M; Kuang Z; Wu M; Wu Z; Wang F; Zhou S; Jing H; Wu W; Wu D; Bai D; Chen B
Cancer Lett; 2022 Jun; 536():215663. PubMed ID: 35381307
[TBL] [Abstract][Full Text] [Related]
5. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
6. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
7. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
[TBL] [Abstract][Full Text] [Related]
8. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
[TBL] [Abstract][Full Text] [Related]
9. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
[TBL] [Abstract][Full Text] [Related]
10. Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells.
Kimura K; Kuwahara A; Suzuki S; Nakanishi T; Kumagai I; Asano R
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859608
[TBL] [Abstract][Full Text] [Related]
11. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
[TBL] [Abstract][Full Text] [Related]
12. BCMAxCD3 Bispecific Yields Robust Responses in Myeloma.
Cancer Discov; 2023 Jun; 13(6):1280. PubMed ID: 37075091
[TBL] [Abstract][Full Text] [Related]
13. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
[TBL] [Abstract][Full Text] [Related]
14. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
15. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
Cheng Y; Zheng X; Wang X; Chen Y; Wei H; Sun R; Tian Z; Sun H
Cancer Biol Med; 2020 Nov; 17(4):1026-1038. PubMed ID: 33299651
[TBL] [Abstract][Full Text] [Related]
16. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
King LA; Toffoli EC; Veth M; Iglesias-Guimarais V; Slot MC; Amsen D; van de Ven R; Derks S; Fransen MF; Tuynman JB; Riedl T; Roovers RC; Adang AEP; Ruben JM; Parren PWHI; de Gruijl TD; van der Vliet HJ
Cancer Immunol Res; 2023 Sep; 11(9):1237-1252. PubMed ID: 37368791
[TBL] [Abstract][Full Text] [Related]
17. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
Aschmoneit N; Kühl L; Seifert O; Kontermann RE
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
[TBL] [Abstract][Full Text] [Related]
18. T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
Quitt O; Luo S; Meyer M; Xie Z; Golsaz-Shirazi F; Loffredo-Verde E; Festag J; Bockmann JH; Zhao L; Stadler D; Chou WM; Tedjokusumo R; Wettengel JM; Ko C; Noeßner E; Bulbuc N; Shokri F; Lüttgau S; Heikenwälder M; Bohne F; Moldenhauer G; Momburg F; Protzer U
J Hepatol; 2021 Nov; 75(5):1058-1071. PubMed ID: 34171437
[TBL] [Abstract][Full Text] [Related]
19. B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.
Wu MR; Zhang T; Gacerez AT; Coupet TA; DeMars LR; Sentman CL
J Immunol; 2015 Jun; 194(11):5305-11. PubMed ID: 25911747
[TBL] [Abstract][Full Text] [Related]
20. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
